We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ferritin Favors Tumor Growth by Blocking an Inhibitor of New Blood Vessel Formation

By LabMedica International staff writers
Posted on 14 Apr 2009
Cancer researchers have found that the serum iron transport protein ferritin stimulates tumor growth and expansion by blocking the antiangiogenic activity of another blood protein, HKa (cleaved high molecular weight kininogen).

The current study was prompted by findings that ferritin levels were often elevated in cancer patients. More...
"It has been known for a long time that levels of ferritin are increased in people with tumors, but it has never been understood why that happens," explained senior author Dr. Suzy V. Torti, associate professor of biochemistry at Wake Forest University (Winston-Salem, NC, USA). "Ferritin appears to play an important role in blood vessel formation. Further, the interaction between ferritin and HKa may represent a new area of interest for possible drug development."

The investigators worked with a line of immunocompromised mice into which they transplanted cells from human prostate tumors. They reported in the January 6, 2009, online edition of the journal the Proceedings of the [U.S.] National Academy of Sciences (PNAS) that ferritin bound to HKa with high affinity and that ferritin blocked the antiangiogenic effects of Hka. This interaction, which was independent of ferritin's iron content, enhanced the migration, assembly, and survival of HKa-treated endothelial cells. Peptide mapping revealed that ferritin bound to a 22-amino acid subdomain of HKa that was critical to its antiangiogenic activity.

In the mouse xenograft study, coinjection of Hka and cancer cells produced small tumors with inhibited blood vessel formation. However, addition of ferritin to the mixture of HKa and cancer cells restored blood vessel formation, promoting tumor growth.

"Blood vessels can either be helpful, for example in wound healing, or they can be harmful, for example by favoring tumor growth," said Dr. Torti. "Our new finding is that the interaction between ferritin and HKa can influence blood vessel formation. This finding could serve as the basis for strategies to either inhibit or stimulate blood vessels. This opens up a new realm of potential ways to treat tumors or other conditions that depend on new blood vessel formation."

Related Links:
Wake Forest University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.